Should you buy Sirtex Medical Limited today?

Sirtex Medical Limited (ASX:SRX) has recovered 45% of its value, yet it remains well below its price from that fateful day last week which saw its shares plummet.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

When people invest in the biotechnology sector, they normally do so knowing the high level of risks involved. Indeed, it's been shown time and again that one bad result can be deadly to a biotech's valuation.

But when life-sciences company Sirtex Medical Limited (ASX: SRX) plummeted as much as 62% to an intraday low of $14.80 last week (down from $39), the shock was widespread throughout the market.

Indeed, the results of its SIRFLOX trial had been so widely expected to come back positive that investors were willing to pay more than 91 times Sirtex's 2014 financial year earnings for the stock.

One analyst had even slapped a $50.40 price target on the stock, which had it trading on a trailing price-earnings ratio of almost 119 times.

A result no-one was expecting

Unfortunately, the results were not what the market were expecting. While the company said that data from the trial showed a statistically significant improvement in the secondary endpoint of progression free survival in the liver, the primary endpoint of the trial was not met which was to show overall progression free survival.

Given the lofty premium at which the stock was trading – where success was all but expected – it perhaps shouldn't have come as such a surprise that the market reacted so swiftly.

However, since hitting that low of $14.80, the stock has recovered somewhat. In fact, the lucky investors who bought in at the bottom are sitting on a remarkable 45.6% gain after just seven trading days. By comparison, the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) has risen a much more modest 2.9%.

Should you buy Sirtex Medical?

First and foremost, it should be noted that the biotechnology sector isn't for the fainthearted. As Sirtex and various other biotech stocks, including Acrux Limited (ASX: ACR) and GI Dynamics Inc (ASX: GID) have highlighted recently how the biotech sector can bring big losses.

While the final results of the SIRFLOX study will be released in May 2015, there could be more volatility between now and then, and it's anyone's guess as to whether the results will yield a positive or negative surprise. With Sirtex's shares having regained almost half of their value since that fateful day last week, there could be some profit-taking as investors look to limit their risks.

Sirtex is a great company, and one of Australia's few biotechnology stocks possessing true promise. While it is certainly one for long-term investors who are willing to look beyond its recent setback to consider, it is also not one for the risk-averse.

Motley Fool contributor Ryan Newman does not own shares in any of the companies mentioned. You can follow Ryan on Twitter @ASXvalueinvest. The Motley Fool’s purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead.  This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »